Navigation Links
EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
Date:5/15/2009

er expanded its clinical development efforts for ENMD-2076 and has commenced a Phase 1 study in patients with relapsed or refractory leukemia. The study will be conducted at the Princess Margaret Hospital in Toronto, Ontario and Karen Yee, M.D., will serve as Principal Investigator. Although the primary endpoints of the study include defining the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of ENMD-2076 administered orally in patients with relapsed or refractory leukemia, the study will also evaluate pharmacodynamic effects of ENMD-2076 by collaborating with Dr. David Hedley, Department of Molecular Oncology, Ontario Cancer Institute (OCI).

Dr. Mark R. Bray, EntreMed Vice President, Research commented, "We are very excited to be working with Dr. Hedley and his staff, who have considerable experience in evaluating the mechanistic effects of kinase inhibitors like ENMD-2076 in cancer patients. The close proximity of EntreMed scientific personnel based in Toronto to our clinical collaborators at the OCI will facilitate our ability to obtain the maximum value from this study and its correlative components."

In addition, the U.S. Food and Drug Administration (FDA) granted orphan drug designation for ENMD-2076 for the treatment of ovarian cancer. Several ovarian cancer patients participated in the ENMD-2076 Phase 1 study in solid tumors and will be included in the data presentations at ASCO. Orphan drug is a designation by the Food and Drug Administration indicating a therapy developed to treat diseases that affect fewer than 200,000 persons in the United States. Sponsors of drugs granted orphan designation qualify for tax credit and marketing exclusivity incentives of the Orphan Drug Act. Previously EntreMed had received orphan drug designation for ENMD-2076 for multiple myeloma.

EntreMed Vice President and Chief Medical Officer, Carolyn F. Sidor, M.D., M.B.A., commented, "The clinical development
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
2. EntreMed to Present at the New York Society of Security Analysts Industry Conference
3. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
4. EntreMed Reports Third Quarter 2008 Financial Results
5. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
6. EntreMed to Present at BioPartnering Europe Conference
7. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
8. EntreMed Reports Second Quarter 2008 Financial Results
9. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
10. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2014)... Boehringer Laboratories Inc., with a forty ... announce the successful broadcast of a live surgery by ... MD, FACS, FAMBS, and Maher El Chaar, MD, FACS, ... , This sleeve gastrectomy surgery was performed and ... four hundred surgeons from around the world during the ...
(Date:9/12/2014)... Advancing the front lines of ... and biological threats is the mission of an ... (WPI) and the Georgian National Academy of Sciences, ... and Security Programme of the North Atlantic Treaty ... Workshop series, the event is titled “Nanotechnology to ...
(Date:9/12/2014)... On Thursday, September 11, 2014, the NASDAQ Composite ended ... the day 0.12% lower at 17,049.00, and the S&P 500 ... as seven out of ten sectors ended the session in ... day at 741.83, down 0.33%, while the index has advanced ... on the following equities: Exelixis Inc. (NASDAQ: EXEL ...
(Date:9/11/2014)... induced pluripotent stem cells (hiPSCs), researchers have gained ... revealing the altered patterns of neuronal signaling associated ... neurons derived from the hiPSCs of healthy individuals ... which triggered these stem cells to release neurotransmitters, ... function and are linked to various disorders. By ...
Breaking Biology Technology:Boehringer Laboratories, Inc. Announces Live Surgery Using Innovative System to Calibrate Sleeve Gastrectomy 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5Stem cells help researchers understand how schizophrenic brains function 2
... to Vice President and Helena Rojas to Director of Global Business ... ... 2009 -- CSOFT International Ltd., a leading provider of multilingual localization, ... promotion of Matt Arney to Vice President of Global Business Development ...
... using carbon nanotubes only billionths of a meter ... that could make airplane skins and other products ... in cost. , Moreover, advanced composites reinforced ... times more electrically conductive than their counterparts without ...
... (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" or the "Company") ... December 31, 2008. , "In 2008, we selected our ... President and CEO of Oncolytics. "The selection of head ... in our US and UK clinical studies, and the ...
Cached Biology Technology:Localization and Translation Leader CSOFT International Ltd. Recognizes Efforts of Two Key Members of its Business Development Team 2Localization and Translation Leader CSOFT International Ltd. Recognizes Efforts of Two Key Members of its Business Development Team 3MIT: 'Nanostitching' could strengthen airplane skins, more 2Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 2Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 3Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 4Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 5Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 6Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 7Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 8Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 9
(Date:9/15/2014)... is available in German . ... is straightforward: it doubles, divides in the middle and ... long assumed that cells of the same kind are ... Bulgheresi,s team, University of Vienna, revealed that two non-model ... perceivable by the naked eye. These findings have been ...
(Date:9/15/2014)... The current Ebola virus outbreak in West Africa, which ... need for a deeper understanding of the molecular biology ... development of vaccines or antiviral drugs to treat or ... University of Virginia (UVA), USA under the leadership ... Derewenda, a structural biologist has obtained the crystal ...
(Date:9/15/2014)... At nearly 100 feet long and weighing as much as ... the planet, and by far the heaviest living thing ever ... anything in common with the tiniest fish larvae, which measure ... of a gram, right? , Not so fast, says ... Mathematics, of Organismic and Evolutionary Biology, and of Physics. ...
Breaking Biology News(10 mins):Think big! Bacteria breach cell division size limit 2Protein secrets of Ebola virus 2The science behind swimming 2The science behind swimming 3
... have added one more trick to the amazing repertoire ... signals to nerve cells. , Nanotubes, tiny hollow carbon ... hair, are already famed as one of the most ... as steel and one-sixth as dense, able to conduct ...
... 2006 is shaping up as the worst year for California's ... of evolution and ecology at UC Davis. , That's a ... migrated through the Central Valley. But other species have seen ... region altogether. , "It has been the worst spring for ...
... used in Chinese medicine to treat the symptoms of ... reverses some of the pancreatic dysfunctions that underlie the ... Metabolism. The chemical therefore represents a useful starting point ... drug could offer a big advance, the group added, ...
Cached Biology News:Nanotubes used for first time to send signals to nerve cells 2Where have all the butterflies gone? 2Gardenia fruit compound starting point for diabetes therapy 2
poliovirus receptor-related 2 (herpesvirus entry mediator B), mRNA...
...
cysteine and glycine-rich protein 2,...
... agent and DNA-topoisomersae II inhibitor (IC50 = 59.2 ... C 29 H 32 O 13 ... Store at: RT ... Soluble to 100 mM ...
Biology Products: